科学家正致力于开发针对痤疮的疫苗,制药公司赛诺菲(Sanofi)利用mRNA技术重点攻击引发炎症的细菌蛋白 1。痤疮是一种影响约85%青少年的常见皮肤问题,其主要的致病菌为痤疮丙酸杆菌(Cutibacterium acnes),该菌产生的CAMP2和HylA等蛋白质会引发皮肤炎症 1。目前的研发核心在于中和这些致病因子,赛诺菲正在开展针对CAMP2蛋白的mRNA疫苗研究 1。此前已有初步科学依据支持这一方向:2018年的一项研究显示,靶向CAMP2能在小鼠及体外人体组织中观察到炎症减少;而2023年的另一项研究则表明,靶向HylA酶同样能减轻小鼠体内的痤疮样炎症 1。
目前,赛诺菲已启动两项1-2期临床试验以评估该疫苗的安全性及作为治疗手段的有效性 1。这两项试验分别计划招募800名中重度痤疮患者和228名轻度痤疮参与者 1。受试者年龄限制在18至45岁之间,且由于所有参与者均已患有痤疮,这些试验旨在验证疫苗的治疗作用而非预防效果 1。尽管动物实验显示出减轻炎症的潜力,但尚未证明该疫苗能在人类中彻底清除痤疮,研发过程仍面临长期安全性以及对皮肤微生物群潜在影响等技术挑战 1。赛诺菲发言人称,痤疮不仅关乎皮肤健康,更“触及自信和心理健康” 1。
Scientists and pharmaceutical companies are developing a vaccine to treat acne, with Sanofi leading efforts to create an mRNA-based therapy targeting specific bacterial proteins 1. Acne affects approximately 85% of adolescents 1. The condition is primarily driven by the bacterium Cutibacterium acnes (C. acnes), which produces proteins such as CAMP2 and HylA that trigger inflammation 1. Sanofi is specifically focusing on a vaccine against CAMP2, building on previous research that demonstrated reduced inflammation in mice and human tissue samples when this protein was targeted 1. Additionally, a 2023 study found that targeting the HylA enzyme reduced acne-like inflammation in mice 1.
Current clinical trials are evaluating the safety and therapeutic efficacy of the vaccine in adult patients aged 18 to 45 who already have acne, meaning the treatment aims to manage existing conditions rather than prevent them 1. Sanofi has launched two Phase 1-2 trials: one seeking 800 participants with moderate-to-severe acne and another recruiting 228 individuals with mild cases 1. While animal studies suggest the vaccine can reduce inflammation, it has not yet been proven to completely clear acne in humans, and challenges remain regarding long-term safety and potential impacts on the skin microbiome 1. A Sanofi spokesperson emphasized that the condition extends beyond physical symptoms, noting that it "touches confidence and mental health" 1.
评论
还没有评论,欢迎留下第一条。